BELVIQ XR is a Oral Tablet, Film Coated, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Eisai Inc.. The primary component is Lorcaserin Hydrochloride Hemihydrate.
| Product ID | 62856-535_3097271d-6dae-4dce-91c2-783e31678eb6 |
| NDC | 62856-535 |
| Product Type | Human Prescription Drug |
| Proprietary Name | BELVIQ XR |
| Generic Name | Lorcaserin Hydrochloride Hemihydrate |
| Dosage Form | Tablet, Film Coated, Extended Release |
| Route of Administration | ORAL |
| Marketing Start Date | 2016-07-15 |
| Marketing Category | NDA / NDA |
| Application Number | NDA208524 |
| Labeler Name | Eisai Inc. |
| Substance Name | LORCASERIN HYDROCHLORIDE HEMIHYDRATE |
| Active Ingredient Strength | 20 mg/1 |
| Pharm Classes | Serotonin-2c Receptor Agonist [EPC],Serotonin 2c Receptor Agonists [MoA],Cytochrome P450 2D6 Inhibitors [MoA] |
| DEA Schedule | CIV |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
| Marketing Start Date | 2016-07-15 |
| Marketing End Date | 2022-05-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA208524 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2016-07-15 |
| Ingredient | Strength |
|---|---|
| LORCASERIN HYDROCHLORIDE HEMIHYDRATE | 20 mg/1 |
| SPL SET ID: | 7cbbb12f-760d-487d-b789-ae2d52a3e01f |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 62856-535 | BELVIQ XR | lorcaserin hydrochloride hemihydrate |
| 62856-529 | Belviq | lorcaserin hydrochloride hemihydrate |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() BELVIQ XR 86693918 4908131 Live/Registered |
EISAI INC. 2015-07-15 |
![]() BELVIQ XR 86693911 4922297 Live/Registered |
Arena Pharmaceuticals GmbH 2015-07-15 |
![]() BELVIQ XR 86330779 4695303 Live/Registered |
EISAI INC. 2014-07-08 |